PMID- 25363231
OWN - NLM
STAT- MEDLINE
DCOM- 20150410
LR  - 20151119
IS  - 1365-2141 (Electronic)
IS  - 0007-1048 (Linking)
VI  - 168
IP  - 5
DP  - 2015 Mar
TI  - NFKB1 -94ins/delATTG polymorphism is a novel prognostic marker in first 
      line-treated multiple myeloma.
PG  - 679-88
LID - 10.1111/bjh.13197 [doi]
AB  - Nuclear factor kappa B (NFKB) plays an important role in multiple myeloma (MM), 
      and bortezomib affects this pathway. We retrospectively analysed the effect of 
      the NFKB1 -94ins/delATTG polymorphism on the survival of 295 MM patients treated 
      at a single centre. The median progression-free survival (PFS) was 790 (659-921) 
      d in patients with NFKB1 homozygous insertion genotype (I/I, n = 99) and 624 
      (515-733) d in deletion-carriers (I/D&D/D, n = 196, P = 0.013). In multivariate 
      analysis, I/I carriers showed a favourable PFS compared to I/D&D/D with a hazard 
      ratio of 0.622 (0.457-0.847), P = 0.003, in addition to international staging 
      system (ISS) score, fluorescence in situ hybridization (FISH) risk score, age and 
      bortezomib treatment. I/I patients benefited more from bortezomib treatment [PFS 
      902 (703-1101) and 580 (343-817), P = 0.008] than I/D&D/D patients [PFS 659 
      (487-831) and 488 (323-653), P = 0.531]; in addition the beneficial effect of low 
      ISS score was not observed in the I/D&D/D group [PFS 639 (454-824) and 650 
      (458-842), P = 0.226], while it was clear in I/I patients [PFS 1140 (803-1477) 
      and 580 (408-752), P < 0.001]. We conclude that homozygous carriers of the 
      insertion allele of the NFKB1 -94ins/delATTG polymorphism have a better prognosis 
      and probably benefit more from bortezomib treatment than MM patients carrying the 
      deletion allele.
CI  - (c) 2014 John Wiley & Sons Ltd.
FAU - Varga, Gergely
AU  - Varga G
AD  - 3rd Department of Internal Medicine, Semmelweis University, Budapest, Hungary.
FAU - Mikala, Gabor
AU  - Mikala G
FAU - Andrikovics, Hajnalka
AU  - Andrikovics H
FAU - Koszarska, Magdalena
AU  - Koszarska M
FAU - Balassa, Katalin
AU  - Balassa K
FAU - Adam, Emma
AU  - Adam E
FAU - Kozma, Andras
AU  - Kozma A
FAU - Tordai, Attila
AU  - Tordai A
FAU - Masszi, Tamas
AU  - Masszi T
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20141103
PL  - England
TA  - Br J Haematol
JT  - British journal of haematology
JID - 0372544
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Boronic Acids)
RN  - 0 (NF-kappa B p50 Subunit)
RN  - 0 (NFKB1 protein, human)
RN  - 0 (Pyrazines)
RN  - 69G8BD63PP (Bortezomib)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Alleles
MH  - Antineoplastic Agents/*administration & dosage
MH  - *Base Sequence
MH  - Biomarkers, Tumor/*genetics
MH  - Boronic Acids/*administration & dosage
MH  - Bortezomib
MH  - Disease-Free Survival
MH  - Female
MH  - Homozygote
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Multiple Myeloma/drug therapy/genetics/mortality
MH  - NF-kappa B p50 Subunit/*genetics
MH  - *Polymorphism, Genetic
MH  - Pyrazines/*administration & dosage
MH  - Retrospective Studies
MH  - *Sequence Deletion
MH  - Survival Rate
OTO - NOTNLM
OT  - NFKB1
OT  - bortezomib
OT  - multiple myeloma
OT  - nuclear factor kappa B
OT  - polymorphism
EDAT- 2014/11/05 06:00
MHDA- 2015/04/11 06:00
CRDT- 2014/11/04 06:00
PHST- 2014/07/12 00:00 [received]
PHST- 2014/09/18 00:00 [accepted]
PHST- 2014/11/04 06:00 [entrez]
PHST- 2014/11/05 06:00 [pubmed]
PHST- 2015/04/11 06:00 [medline]
AID - 10.1111/bjh.13197 [doi]
PST - ppublish
SO  - Br J Haematol. 2015 Mar;168(5):679-88. doi: 10.1111/bjh.13197. Epub 2014 Nov 3.